Poor
Not Aligned
Patient Risk:
Moderate
Summary
The response contains multiple statements with specific clinical timing, risk factors, and numeric management thresholds that are not supported by the provided FDA label excerpts. Several label-supported hepatic-adverse-effect concepts are over-generalized or misrepresented (e.g., implying normalization after discontinuation despite the label stating hepatic dysfunction may occur after discontinuation).
Category Scores
Accurate Statements
In rare cases, liver enzyme elevations persisted beyond discontinuation of tigecycline.
Supported by 5.4: hepatic dysfunction may occur after the drug has been discontinued.
In clinical trials, tigecycline-related liver enzyme increases often occur during treatment.
Partially supported by 6.1 footnote: LFT abnormalities occurred more frequently in the post-therapy period and occurred more often on therapy (but frequency term 'often' is not directly quantified).
Unsupported Statements
Tigecycline has been linked to temporary rises in liver enzymes such as ALT and AST.
5.4 mentions transaminase increases but does not specify ALT/AST nor that they are temporary.
Tigecycline-related liver enzyme increases usually return to normal once the antibiotic is stopped.
Contradicted by 5.4 stating hepatic dysfunction may occur after discontinuation; the label does not support 'usually return to normal' after stopping.
Patients with baseline liver disease appear more at risk of persistent liver enzyme elevations from tigecycline.
Not supported in provided excerpts; 5.4 does not identify baseline liver disease as a persistence risk factor.
Patients receiving extended courses of tigecycline appear more at risk of persistent liver enzyme elevations.
Not supported; duration is not presented as a persistence risk factor in provided excerpts.
Persistent abnormalities require follow-up blood tests.
5.4 recommends monitoring abnormal liver function tests and evaluating risk/benefit, but provided excerpts do not explicitly mandate follow-up blood tests for persistence.
Tigecycline is in the glycylcycline class.
Not supported by provided label excerpts.
Tigecycline's liver safety profile resembles older tetracyclines.
Not supported by provided label excerpts.
Clinical data show fewer cases of severe hepatitis with tigecycline than with minocycline.
Not supported by provided label excerpts.
Spontaneous reporting system data indicate similar overall rates of liver injury reports between tigecycline and other tetracyclines.
Not supported by provided label excerpts.
Long-term data on tigecycline and liver function over years of intermittent use remain limited.
Not supported by provided label excerpts.
Tigecycline is mainly used for acute infections rather than chronic therapy.
Not supported by provided label excerpts (no acute vs chronic usage characterization in the provided sections).
Concurrent use of other drugs known to affect the liver increases the likelihood of liver problems with tigecycline.
5.4 notes some cases involved multiple concomitant medications but does not state that concomitant liver-affecting drugs increase likelihood.
Preexisting liver conditions increase the likelihood of liver problems with tigecycline.
Not supported by provided excerpts.
Prolonged treatment durations increase the likelihood of liver problems with tigecycline.
Not supported by provided excerpts.
Some patients who received tigecycline for more than two weeks showed cumulative risk trends.
Not supported by provided excerpts (no >2 week threshold or cumulative risk trend).
Clinicians check liver function tests before starting tigecycline.
5.4 describes monitoring when abnormal liver function tests develop; the provided excerpts do not instruct baseline pre-start LFT checks.
Any significant rise in ALT or AST above five times the upper limit of normal usually prompts discontinuation or switching to an alternative antibiotic.
5.4 provides monitoring/evaluation guidance and does not provide numeric ALT/AST thresholds or a rule for discontinuation/switching.
Tigecycline's liver enzyme increases usually return to normal once the antibiotic is stopped.
Not supported; see contradiction with 5.4.
Contradictions
High
AI Statement
Tigecycline-related liver enzyme increases usually return to normal once the antibiotic is stopped.
Label Reference
5.4: hepatic dysfunction may occur after the drug has been discontinued.
Important Omissions
Label-supported monitoring approach details: 5.4 specifies monitoring for evidence of worsening hepatic function and evaluating risk/benefit of continuing, including the possibility of hepatic dysfunction after discontinuation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Overstated/unsupported claims (e.g., 'usually return to normal' after stopping, numeric threshold-based discontinuation, and unsubstantiated risk factors/duration effects) could lead to inaccurate clinical interpretation relative to the label’s more cautious monitoring language. The label does support hepatic adverse effects and monitoring of abnormal LFTs, but the response adds management specifics not present in the excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple hepatic-adverse-effect statements include specific clinical timelines, risk factors (baseline liver disease, extended courses), and an ALT/AST >5x ULN discontinuation rule that are not supported by the provided label excerpts, plus one statement contradicts the label (assumed return to normal after stopping).
Suggested Improvement
Remove or rephrase unsupported specifics to match 5.4/6.1 language (e.g., discuss transaminase and bilirubin/prothrombin time increases; emphasize monitoring abnormal liver function tests and evaluating risk/benefit of continuing; avoid numeric ALT/AST thresholds and avoid implying normalization after discontinuation).